NAD+ in brain aging and neurodegenerative disorders

Plain-language summary

Published 2019 in Cell Metabolism, this work by Lautrup S and collaborators tackles a specific question within nad-focused NMN/NAD+ research.

Key findings reported by the authors

• Brain NAD+ decline with age
• Neurodegenerative disease links
• Therapeutic NAD+ replenishment outlook

What this means for Malaysian buyers

For readers in Malaysia weighing whether to start or continue NMN supplementation, this paper sits at the strong end of the evidence spectrum. Strong-tier human placebo-controlled trial data carries the most weight in our editorial framework - treat findings as actionable signal, but always pair with at least one replication. Findings here are most directly relevant to nad decisions, with secondary relevance to brain and review. Our editorial methodology weights human placebo-controlled trials above mouse mechanistic work above review articles.